A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis

Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Larysa Sanchez, Heather Landau, Cara Rosenbaum, Alex Abrahams, Cindy Chin, Brielle Liotta, Natalie Agudo, Sheetal Ramnath, Elizabeth Hoover, Hafsa Rahman, Umut Ozbek, Oscar Lahoud, Hani Hassoun, Keren Osman
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research